An Italian cost-effectiveness analysis of paclitaxel albumin (nab®-paclitaxel) plus gemcitabine vs gemcibatine alone for metastatic pancreatic cancer patients: The APICE study

被引：0
|
作者：
Lazzaro, C. [1 ]
Barone, C. [2 ]
Caprioni, F. [3 ]
Cascinu, S. [4 ]
Falcone, A. [5 ]
Maiello, E. [6 ]
Milella, M. [7 ]
Pinto, C. [8 ]
Reni, M. [9 ]
Tortora, G. [10 ]
机构：
[1] Studio Econ Sanit, Pharmacoecon, Milan, Italy
[2] Policlin Univ A Gemelli, UOC Oncol Med, Med Interna, Rome, Italy
[3] IST Ist Nazl Ric Canc, IRCCS AOU San Martino, Oncol Med 1, Genoa, Italy
[4] Azienda Osped Univ Policlin Modena, Med Oncol, Modena, Italy
[5] Azienda Osped Univ S Chiara, Dept Oncol Presidio Ospedaliero, Pisa, Italy
[6] IRCCS Casa Sollievo Sofferenza, Dept Hematol Oncol, San Giovanni Rotondo, Italy
[7] Ist Regina Elena, SC Oncol Med A, Rome, Italy
[8] Azienda Osped Arcispedale Santa Maria Nuova IRCCS, SC Oncol, Reggio Emilia, Italy
[9] IRCCS San Raffaele, Med Oncol, Milan, Italy
[10] Azienda Osped Univ Integrata Verona Borgo Roma, Med Oncol, Verona, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw377.24
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1045P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] AN INDIRECT TREATMENT COMPARISON AND COST-EFFECTIVENESS ANALYSIS COMPARING FOLFIRINOX WITH NAB-PACLITAXEL PLUS GEMCITABINE FOR FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC PANCREATIC CANCER
    Hollmann, S.
    Alloul, K.
    Attard, C.
    Kavan, P.
    ANNALS OF ONCOLOGY, 2014, 25 : 11 - 11
  • [22] Nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Resected Pancreatic Cancer in a Phase III Trial (APACT)
    Tempero, Margaret
    Cardin, Dana
    Biankin, Andrew V.
    Goldstein, David
    Moore, Malcolm
    O'Reilly, Eileen
    Philip, Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Li, Mingyu
    Lu, Brian
    GASTROENTEROLOGY, 2015, 148 (04) : S944 - S944
  • [23] Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer
    Borazanci, Erkut
    Von Hoff, Daniel D.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 8 (07) : 739 - 747
  • [24] Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
    Junko Tahara
    Kyoko Shimizu
    Nao Otsuka
    Junichi Akao
    Yukiko Takayama
    Katsutoshi Tokushige
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 245 - 250
  • [25] Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
    Tahara, Junko
    Shimizu, Kyoko
    Otsuka, Nao
    Akao, Junichi
    Takayama, Yukiko
    Tokushige, Katsutoshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (02) : 245 - 250
  • [26] Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients
    Ingram, Myles A.
    Lauren, Brianna N.
    Pumpalova, Yoanna
    Park, Jiheum
    Lim, Francesca
    Bates, Susan E.
    Kastrinos, Fay
    Manji, Gulam A.
    Kong, Chung Yin
    Hur, Chin
    CANCER REPORTS, 2022, 5 (09)
  • [27] The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer
    Martina Catalano
    Giuseppe Aprile
    Raffaele Conca
    Roberto Petrioli
    Monica Ramello
    Giandomenico Roviello
    Scientific Reports, 12
  • [28] The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer
    Catalano, Martina
    Aprile, Giuseppe
    Conca, Raffaele
    Petrioli, Roberto
    Ramello, Monica
    Roviello, Giandomenico
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [29] Impact of nab-paclitaxel (nab-P) plus gemcitabine (G) vs gemcitabine alone on Karnofsky performance status (KPS) in metastatic pancreatic cancer.
    Chiorean, E. Gabriela
    Wan, Yin
    Whiting, Scott
    Kayitalire, Louis
    Botteman, Marc
    Ji, Xiang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Effectiveness of CA 19.9 in predicting prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine
    Mariani, S.
    Soro, P.
    Liscia, N.
    Balconi, F.
    Camera, S.
    Donisi, C.
    Impera, V.
    Musio, F.
    Persano, M.
    Pireddu, A.
    Pretta, A.
    Tolu, S.
    Pusceddu, V.
    Lai, E.
    Faloppi, L.
    Demurtas, L.
    Ziranu, P.
    Puzzoni, M.
    Scartozzi, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 63 - 63
12345